| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $2,999,996 | 1 | 17 |
Sells | $3,550,703 | 5 | 83 |
| Manning Paul B | director | 1 | $3M | 0 | $0 | $3M |
| Tyagarajan Seshu | Chief Technology Officer | 0 | $0 | 2 | $154,151 | $-154,151 |
| Barone Francesca | Chief Scientific Officer | 0 | $0 | 1 | $235,769 | $-235,769 |
| Tak Paul Peter | Chief Executive Officer | 0 | $0 | 2 | $3.16M | $-3.16M |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent …
Over the last 12 months, insiders at Candel Therapeutics, Inc. have bought $3M and sold $3.55M worth of Candel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Candel Therapeutics, Inc. have bought $3.56M and sold $2.56M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Manning Paul B (director) — $3M.
The last purchase of 550,458 shares for transaction amount of $3M was made by Manning Paul B (director) on 2026‑02‑23.
| 2026-09-11 | Sale | Tak Paul Peter | Chief Executive Officer | 59,379 0.0804% | $10.46 | $620,891 | -6.88% | |
| 2026-09-10 | Sale | Tak Paul Peter | Chief Executive Officer | 220,866 0.306% | $11.50 | $2.54M | -13.11% | |
| 2026-08-17 | Sale | Tyagarajan Seshu | Chief Technology Officer | 7,000 0.0093% | $12.00 | $84,000 | -10.77% | |
| 2026-06-29 | Sale | Tyagarajan Seshu | Chief Technology Officer | 7,000 0.0123% | $10.02 | $70,151 | -1.74% | |
| 2026-06-29 | Sale | Barone Francesca | Chief Scientific Officer | 23,447 0.0415% | $10.06 | $235,769 | -1.74% | |
| 2026-02-23 | Manning Paul B | director | 550,458 1.0995% | $5.45 | $3M | +76.76% | ||
| 2025-07-28 | Sale | Nichols William Garrett | Chief Medical Officer | 937 0.0018% | $6.98 | $6,540 | -15.89% | |
| 2025-06-30 | Sale | Nichols William Garrett | Chief Medical Officer | 781 0.0015% | $5.04 | $3,936 | +12.85% | |
| 2025-03-19 | Sale | Tak Paul Peter | Chief Executive Officer | 400 0.0009% | $9.00 | $3,601 | -38.76% | |
| 2025-03-18 | Sale | Tak Paul Peter | Chief Executive Officer | 25,772 0.0576% | $8.77 | $226,023 | -38.21% | |
| 2025-03-18 | Sale | Barone Francesca | Chief Scientific Officer | 32,146 0.0718% | $8.76 | $281,673 | -38.21% | |
| 2025-03-18 | Sale | Nichols William Garrett | Chief Medical Officer | 45,316 0.1012% | $8.76 | $396,995 | -38.21% | |
| 2025-03-17 | Sale | Tyagarajan Seshu | Chief Technology Officer | 31,278 0.0703% | $8.82 | $275,947 | -38.17% | |
| 2025-03-17 | Sale | Schoch Charles | See Remarks | 5,000 0.0112% | $8.83 | $44,169 | -38.17% | |
| 2025-01-15 | Sale | Tak Paul Peter | Chief Executive Officer | 21,704 0.0476% | $7.22 | $156,811 | -30.13% | |
| 2025-01-15 | Sale | Barone Francesca | Chief Scientific Officer | 13,534 0.0297% | $7.22 | $97,783 | -30.13% | |
| 2025-01-15 | Sale | Tyagarajan Seshu | Chief Technology Officer | 14,322 0.0314% | $7.22 | $103,476 | -30.13% | |
| 2025-01-15 | Sale | Nichols William Garrett | Chief Medical Officer | 10,428 0.0229% | $7.22 | $75,342 | -30.13% | |
| 2025-01-15 | Sale | Schoch Charles | See Remarks | 9,511 0.0209% | $7.22 | $68,717 | -30.13% | |
| 2025-01-08 | Sale | Tak Paul Peter | Chief Executive Officer | 21,172 0.0454% | $8.22 | $173,996 | -36.03% |
| Manning Paul B | director | 2763527 3.6116% | $24.37M | 4 | 0 | <0.0001% |
| Tak Paul Peter | Chief Executive Officer | 113321 0.1481% | $999,491.22 | 3 | 9 | <0.0001% |
| Barone Francesca | Chief Scientific Officer | 77362 0.1011% | $682,332.84 | 1 | 7 | <0.0001% |
| Tyagarajan Seshu | Chief Technology Officer | 76865 0.1005% | $677,949.30 | 2 | 8 | <0.0001% |
| Martell Christopher | director | 152000 0.1986% | $1.34M | 3 | 0 | <0.0001% |
| PAPA JOSEPH C | director | 38032 0.0497% | $335,442.24 | 2 | 0 | <0.0001% |
| Canepa John J | Chief Financial Officer | 10125 0.0132% | $89,302.50 | 1 | 0 | <0.0001% |
| Nguyen Diem | director | 10000 0.0131% | $88,200.00 | 1 | 0 | <0.0001% |
| Caffo Nathan | Chief Business Officer | 6000 0.0078% | $52,920.00 | 1 | 0 | <0.0001% |
| Amello Jason | Chief Financial Officer | 5568 0.0073% | $49,109.76 | 2 | 0 | <0.0001% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$1,108,102,085 | 66 | 36.91% | $755.04M | |
$1,344,238 | 38 | 23.07% | $639.18M | |
$59,156,363 | 22 | 29.25% | $686.5M |
| Increased Positions | 45 | +54.88% | 2M | +8.01% |
| Decreased Positions | 31 | -37.8% | 896,644 | -3.95% |
| New Positions | 13 | New | 303,513 | New |
| Sold Out Positions | 13 | Sold Out | 584,269 | Sold Out |
| Total Postitions | 96 | +17.07% | 24M | +4.06% |
| Fmr Llc | $44,790.00 | 14.97% | 8.23M | -50 | <0.01% | 2025-09-30 |
| Acorn Capital Advisors, Llc | $14,038.00 | 4.69% | 2.58M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $12,944.00 | 4.33% | 2.38M | +77,485 | +3.37% | 2025-09-30 |
| Vanguard Group Inc | $10,919.00 | 3.65% | 2.01M | +219,563 | +12.28% | 2025-09-30 |
| Portolan Capital Management, Llc | $7,530.00 | 2.52% | 1.38M | -237,586 | -14.65% | 2025-09-30 |
| Geode Capital Management, Llc | $5,049.00 | 1.69% | 928,197 | +24,227 | +2.68% | 2025-09-30 |
| Halter Ferguson Financial Inc. | $3,797.00 | 1.27% | 698,004 | -78,512 | -10.11% | 2025-09-30 |
| State Street Corp | $3,747.00 | 1.25% | 688,766 | +36,787 | +5.64% | 2025-09-30 |
| Sands Capital Alternatives, Llc | $2,208.00 | 0.74% | 405,837 | 0 | 0% | 2025-09-30 |
| Northern Trust Corp | $1,669.00 | 0.56% | 306,775 | +18,912 | +6.57% | 2025-09-30 |